Animal models of systemic lupus erythematosus and their applications in drug discovery

Xin, Yue; Zhang, Bo; Zhao, Jin; Liu, Qianmei; Yin, Haoyuan; Lu, Qianjin

doi:10.1080/17460441.2022.2050691

Cited by 3 publications

(2 citation statements)

References 101 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…According to our knowledge, our study is the first population-based study to evaluate the association of fish oil supplementation with SLE incidence. A previous animal study demonstrated that dietary fish oil supplementation delayed the onset of SLE in NZB/W F1 mice [ 21 ], a commonly used mouse model of SLE that spontaneously develops SLE characteristics as they age [ 36 ]. Another animal study showed that dietary ω-3 PUFA (DHA) supplementation prevented the development and progression of SLE in NZB/W F1 mice treated with crystalline silica (cSiO2), a unique model for environment-triggered SLE [ 37 ].…”

Section: Discussionmentioning

confidence: 99%

Fish oil supplementation and risk of incident systemic lupus erythematosus: a large population-based prospective study

Chen,

Li,

Gao

et al. 2024

Nutr J

View full text Add to dashboard Cite

Background Although fish oil has been considered to have an anti-inflammatory effect and has been proven to play a beneficial role in the incidence of numerous diseases, the association between fish oil supplementation and the risk of systemic lupus erythematosus (SLE) is still unknown. This study aimed at evaluating the correlation between fish oil use and incident SLE in a large population-based prospective cohort. Methods 390,277 participants without SLE at baseline from the UK Biobank were enrolled. Fish oil use was ascertained through a touchscreen questionnaire at baseline. The incidence of SLE was identified by the International Classification of Diseases version 10 code in medical records or self-report. Cox proportional hazard models were employed to estimate the association between fish oil use and SLE risk. Results Fish oil users accounted for 31.47% of participants. During a median follow-up duration of 11.57 years, 141 participants without fish oil use (4.56/100 000 person-years) and 68 participants with fish oil use (4.78/100 000 person-years) developed SLE. In four models with adjustments for different amounts of confounders, there was no significant difference in the risk of SLE between fish oil users and fish oil non-users (all p-values > 0.05). In subgroup analyses, we found that fish oil supplementation was associated with a lower risk of SLE among females with ultraviolet radiation ≥ 3 h/day (hazard ratio: 0.63, 95% confidence interval: 0.40–0.98), which turned insignificant after further adjustment for female-related factors and sun protection measures. Conclusions No significant association between fish oil use and overall incident SLE was observed, except in females exposed to prolonged ultraviolet radiation. Subgroup analysis suggested that females exposed to prolonged ultraviolet radiation might benefit from fish oil supplementation in terms of preventing SLE, but it needs to be confirmed in further studies.

show abstract

Section: Discussionmentioning

confidence: 99%

Fish oil supplementation and risk of incident systemic lupus erythematosus: a large population-based prospective study

Chen,

Li,

Gao

et al. 2024

Nutr J

View full text Add to dashboard Cite

show abstract

“…Preclinical animal models for SLE serve as an irreplaceable tool in understanding the cellular mechanism implicated in the onset and progression of the disease in conjugation with their genetic and immunological illustration (Li et al, 2017b;Moore et al, 2021a;Perry et al, 2011). Preclinical murine models of SLE range from classic spontaneous models to genetically modified models, inducible models, and humanized models (Richard and Gilkeson, 2018;Xin et al, 2022). Given the prominent level of heterogeneity observed clinically in SLE patients, no single mouse model fully represents the comprehensive clinical spectrum seen in SLE patients.…”

Section: Preclinical Models Of Systemic Lupus Erythematosusmentioning

confidence: 99%

Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes

Babalola,

Arora,

Ganugula

et al. 2023

Pharmacol Rev

View full text Add to dashboard Cite

The role of advanced drug delivery strategies in drug-repositioning and minimizing drug attrition rates, when applied early in drug discovery, is poised to increase the translational impact of various therapeutic strategies in disease prevention and treatment. In this context, drug delivery to the lymphatic system is gaining prominence not only to improve the systemic bioavailability of various pharmaceutical drugs but also to target certain specific diseases associated with the lymphatic system. While the role of the lymphatic system in lupus is known, very little is done to target drugs to yield improved clinical benefits. In this review, we discuss recent advances in drug delivery strategies to treat lupus, the various routes of drug administration leading to improved lymph node bioavailability, and the available technologies applied in other areas that can be adapted to lupus treatment. Moreover, this review also presents some recent findings that demonstrate the promise of lymphatic targeting in a preclinical setting, offering renewed hope for certain pharmaceutical drugs that are limited by efficacy in their conventional dosage forms. These findings underscore the potential and feasibility of such lymphatic drug targeting approaches, to enhance therapeutic efficacy in lupus and minimize off-target effects of the pharmaceutical drugs. Significance StatementThe World Health Organization estimates that there are currently 5 million humans living with some form of lupus. With limited success in lupus drug discovery, turning to effective delivery strategies with existing drug molecules, as well as those in the early stage of discovery, could lead to better clinical outcomes. After all, effective delivery strategies have been proven to improve treatment outcomes.

show abstract

The Therapeutic Effects of Probiotic on Systemic Lupus Erythematosus in Lupus Mice Models: A Systematic Review

Goh,

Maharajan,

Gopinath

et al. 2024

Probiotics & Antimicro. Prot.

View full text Add to dashboard Cite

Animal models of systemic lupus erythematosus and their applications in drug discovery

Cited by 3 publications

References 101 publications

Fish oil supplementation and risk of incident systemic lupus erythematosus: a large population-based prospective study

Fish oil supplementation and risk of incident systemic lupus erythematosus: a large population-based prospective study

Leveraging Lymphatic System Targeting in Systemic Lupus Erythematosus for Improved Clinical Outcomes

The Therapeutic Effects of Probiotic on Systemic Lupus Erythematosus in Lupus Mice Models: A Systematic Review

Contact Info

Product

Resources

About